Rangering i aksjer
#22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Aksjekurs
$0.04959193
Sist synkronisert: 2025-03-17
Handel Abliva AB (publ) (ABLI)
Pris ABLI pris med markedsverdi på B
Markedsverdi av Abliva AB (publ)(ABLI)
Markedsverdi: $79.94M
Per August 2026 har Abliva AB (publ) en markedsverdi på $79.94M. Dette gjør Abliva AB (publ) til det 22998th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Abliva AB (publ) fra 2008 til 2026
ABLI sammenlignet med topp 5 mest populære stocks
| Pris på ABLI |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.211T
|
+6,519,334.37%
|
|
|
|
|
$4.547T
|
+5,687,889.61%
|
|
|
|
|
$4.162T
|
+5,207,166.93%
|
|
|
|
|
$3.593T
|
+4,494,489.39%
|
|
|
|
|
$2.793T
|
+3,493,767.13%
|
